Search results
Results from the WOW.Com Content Network
Infliximab (Remicade) A monoclonal antibody to TNF, proinflammatory cytokine Crohn's disease, rheumatoid arthritis, ankylosing spondylitis: Respiratory infection, fever, hypotension. Predisposes to infections (reactivation of latent TB) Rituximab (Rituxan) A monoclonal antibody to CD20 surface immunoglobulin
osteoarthritis in dogs: Ranibizumab [9] Lucentis: Fab: humanized: VEGF-A: Y: macular degeneration (wet form) Raxibacumab [39] mab: human: anthrax toxin, protective antigen: Y: anthrax (prophylaxis and treatment) Ravagalimab [5] mab: humanized: CD40: Crohn's disease Ravulizumab [26] Ultomiris: mab: humanized: C5: Y: paroxysmal nocturnal ...
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease , ulcerative colitis , rheumatoid arthritis , ankylosing spondylitis , psoriasis , psoriatic arthritis , and Behçet's disease . [ 23 ]
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
The incidence of developing these antibodies is highest in patients receiving intermittent therapy with infliximab, and lowest in patient receiving continuous therapy and concomitant immunosuppressive therapy. Some suggest that the presence of these antibodies causes a decrease in efficacy of infliximab and increased risk of infusion reactions.
Remicade was approved for plaque psoriasis in September 2006. Centocor also markets ReoPro ( abciximab ), a biologic agent indicated as an adjunct to coronary angioplasty ( PTCA ). In 2009, the U.S. FDA approved Simponi , a human monoclonal antibody for treatment for arthritis, which was co-developed with Medarex , Inc. [ 37 ]
I miss the explicit warning for the high risk of reactivation of latent tuberculosis infection (LTBI), which is 5-10% in persons with LTBI on infliximab. Since the classical granuloma formation is absent the reactivation tuberculosis manifests itself in a severe disseminated form. Before startin infliximab screening for LTBI is needed.
The TNF inhibitors, including infliximab, adalimumab and golimumab, are used to inhibit this step during the treatment of ulcerative colitis. [13] After phagocytosing the microbe, the APCs then enter the mesenteric lymph nodes where they present antigens to naive T-cells while also releasing the pro-inflammatory cytokines IL-12 and IL-23 which ...